SunTrust Robinson Humphrey raised ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

UPDATE: Exelixis (EXEL) PT Raised to $33 at Needham & CompanyOctober 16, 2017 10:36 AM Pre-Open Stock Movers 10/16: (TRXC) (RT) (EXEL) Higher; (AMPE) (ADBE) (ISRG) Lower (more...)October 16, 2017 9:32 AM Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaOctober 16, 2017 7:03 AM Exelixis (EXEL) Granted U.S. FDA Priority Review for CABOMETYX as Treatment for Previously Untreated Advanced Renal Cell CarcinomOctober 16, 2017 7:00 AM Exelixis (EXEL) Reports Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall SurvivalOctober 16, 2017 6:59 AM Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell CarcinomaOctober 16, 2017 6:59 AM Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular CarcinomaOctober 16, 2017 6:58 AM